A detailed history of Federated Hermes, Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 623,815 shares of TVTX stock, worth $10.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
623,815
Previous 41,717 1395.35%
Holding current value
$10.7 Million
Previous $342,000 2451.75%
% of portfolio
0.02%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.89 - $15.21 $4.59 Million - $8.85 Million
582,098 Added 1395.35%
623,815 $8.73 Million
Q2 2024

Aug 08, 2024

BUY
$5.26 - $8.28 $219,431 - $345,416
41,717 New
41,717 $342,000
Q3 2023

Nov 13, 2023

BUY
$7.64 - $17.25 $744,831 - $1.68 Million
97,491 New
97,491 $871,000
Q4 2022

Feb 13, 2023

SELL
$18.47 - $26.14 $22,127 - $31,315
-1,198 Reduced 99.92%
1 $0
Q3 2022

Nov 14, 2022

BUY
$22.91 - $28.63 $9,599 - $11,995
419 Added 53.72%
1,199 $30,000
Q2 2022

Aug 15, 2022

SELL
$20.94 - $30.01 $1.8 Million - $2.59 Million
-86,154 Reduced 99.1%
780 $20,000
Q1 2022

May 13, 2022

BUY
$23.61 - $30.6 $845,757 - $1.1 Million
35,822 Added 70.09%
86,934 $2.24 Million
Q4 2021

Feb 14, 2022

BUY
$24.34 - $31.17 $1.17 Million - $1.5 Million
47,971 Added 1527.25%
51,112 $1.59 Million
Q3 2021

Nov 15, 2021

SELL
$12.98 - $25.03 $821,075 - $1.58 Million
-63,257 Reduced 95.27%
3,141 $76,000
Q2 2021

Aug 16, 2021

SELL
$14.11 - $26.4 $3.51 Million - $6.56 Million
-248,419 Reduced 78.91%
66,398 $969,000
Q1 2021

May 13, 2021

BUY
$23.37 - $31.77 $1.16 Million - $1.58 Million
49,583 Added 18.69%
314,817 $7.86 Million
Q4 2020

Feb 12, 2021

BUY
$19.17 - $27.87 $5.08 Million - $7.39 Million
265,234 New
265,234 $7.23 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.